JP2024521902A - スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン - Google Patents

スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン Download PDF

Info

Publication number
JP2024521902A
JP2024521902A JP2023574388A JP2023574388A JP2024521902A JP 2024521902 A JP2024521902 A JP 2024521902A JP 2023574388 A JP2023574388 A JP 2023574388A JP 2023574388 A JP2023574388 A JP 2023574388A JP 2024521902 A JP2024521902 A JP 2024521902A
Authority
JP
Japan
Prior art keywords
alkyl
mmol
leukemia
compound
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521902A5 (https=
Inventor
ツァイ，ウェイ
ダイ，シュエドン
ケロル，オリヴィエ，アレクシス，ジョルジュ
テューリング，ヨハネス，ウィルヘルムス，ジェイ．
デン，シャンジュン
ファン，リチャオ
フ，リチャン
リ，ミン
リウ，リャンジュ
リウ，インタオ
シュー，ヤンピン
パンデ，ヴィニート
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2024521902A publication Critical patent/JP2024521902A/ja
Publication of JP2024521902A5 publication Critical patent/JP2024521902A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023574388A 2021-06-03 2022-06-02 スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン Pending JP2024521902A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/098067 2021-06-03
CN2021098067 2021-06-03
PCT/CN2022/096734 WO2022253289A1 (en) 2021-06-03 2022-06-02 Pyridazines or 1,2,4-triazines substituted by spirocyclic amines

Publications (2)

Publication Number Publication Date
JP2024521902A true JP2024521902A (ja) 2024-06-04
JP2024521902A5 JP2024521902A5 (https=) 2025-06-02

Family

ID=77021000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574388A Pending JP2024521902A (ja) 2021-06-03 2022-06-02 スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン

Country Status (7)

Country Link
US (1) US20250333421A1 (https=)
EP (1) EP4347600A1 (https=)
JP (1) JP2024521902A (https=)
CN (1) CN117425659A (https=)
BR (1) BR112023025436A2 (https=)
CA (1) CA3218340A1 (https=)
WO (1) WO2022253289A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020514388A (ja) * 2017-03-24 2020-05-21 クラ オンコロジー，インク． 血液悪性腫瘍およびユーイング肉腫を処置するための方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102984941B (zh) 2009-09-04 2016-08-17 密执安大学评议会 用于治疗白血病的组合物和方法
WO2014164543A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
AU2016378579A1 (en) 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
US10869868B2 (en) 2016-01-26 2020-12-22 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
JP6991585B2 (ja) 2016-05-02 2022-01-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン メニン阻害剤としてのピペリジン
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
WO2017214367A1 (en) 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
CA3033020A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
AU2017326006B2 (en) 2016-09-16 2021-10-28 Vitae Pharmaceuticals, LLC. Inhibitors of the menin-MLL interaction
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
JP2022503792A (ja) 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020514388A (ja) * 2017-03-24 2020-05-21 クラ オンコロジー，インク． 血液悪性腫瘍およびユーイング肉腫を処置するための方法

Also Published As

Publication number Publication date
BR112023025436A2 (pt) 2024-02-27
CN117425659A (zh) 2024-01-19
CA3218340A1 (en) 2022-12-08
EP4347600A1 (en) 2024-04-10
US20250333421A1 (en) 2025-10-30
WO2022253289A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
JP7781961B2 (ja) 置換直鎖スピロ誘導体
WO2022253167A1 (en) SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES
AU2022272692A1 (en) Substituted spiro derivatives
JP2024518425A (ja) 置換スピロ誘導体
TW202315636A (zh) （ｒ）－ｎ－乙基－５－氟－ｎ－異丙基－２－（（５－（２－（６－（（２－甲氧基乙基）（甲基）胺基）－２－甲基己－３－基）－２，６－二氮雜螺［３．４］辛－６－基）－１，２，４－三𠯤－６－基）氧基）苯甲醯胺苯磺酸鹽
JP2024521902A (ja) スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン
JP7142010B2 (ja) メニン－ｍｌｌ相互作用のアゼパン阻害剤
JP2025540682A (ja) シクロブチル置換二環式化合物
JP2025541695A (ja) 置換１－フェニル－３，４－ジヒドロピリド［３，４－ｄ］ピリミジン－２－オン誘導体
US20260125387A1 (en) (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt
HK40113255A (zh) 取代的直链螺环衍生物
HK40099770A (zh) 哒嗪或被螺环胺取代的1，2，4-三嗪
HK40071760A (en) Substituted straight chain spiro derivatives
HK40064179A (en) Piperazine amide derivative, preparation method therefor, and use thereof in medicine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250523

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260217